New hope for seniors with aggressive blood cancer: targeted combo shows promise
NCT ID NCT04594798
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a targeted drug called polatuzumab vedotin to a standard chemotherapy regimen (R-miniCHP) can help people aged 75 and older with a type of lymphoma called DLBCL. The goal is to see if the combination improves how long patients live without their cancer getting worse. The study enrolled 39 participants and is currently active but no longer recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Rochester
Rochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Can a targeted drug boost standard chemo for an aggressive lymphoma?
- Can a single shot build a cancer army inside the body?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- New drug combo aims to tame aggressive lymphoma in frail patients
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma